Aptose Biosciences Files 8-K
Ticker: APTOF · Form: 8-K · Filed: Nov 22, 2024 · CIK: 882361
Sentiment: neutral
Topics: sec-filing, regulation-fd, financial-statements
Related Tickers: APTOS
TL;DR
APTOS filed an 8-K, standard reporting stuff, no major news.
AI Summary
Aptose Biosciences Inc. filed an 8-K on November 22, 2024, reporting on Regulation FD disclosures and financial statements. The company, formerly known as Lorus Therapeutics Inc. and Imutec Pharma Inc., is incorporated in Canada and operates in the biological products sector. The filing does not contain specific financial figures or new material events beyond the reporting of these items.
Why It Matters
This filing indicates Aptose Biosciences Inc. is fulfilling its reporting obligations with the SEC, which is standard practice for publicly traded companies.
Risk Assessment
Risk Level: low — This is a routine SEC filing for a public company and does not contain new material information that would inherently increase risk.
Key Players & Entities
- Aptose Biosciences Inc. (company) — Registrant
- Lorus Therapeutics Inc. (company) — Former Company Name
- Imutec Pharma Inc (company) — Former Company Name
- November 22, 2024 (date) — Date of Report
FAQ
What is the primary purpose of this 8-K filing by Aptose Biosciences Inc.?
The primary purpose of this 8-K filing is to report on Regulation FD disclosures and to provide financial statements and exhibits, as indicated in the filing details.
When was this 8-K report filed?
This 8-K report was filed on November 22, 2024.
What were Aptose Biosciences Inc.'s former company names?
Aptose Biosciences Inc. was formerly known as Lorus Therapeutics Inc. and Imutec Pharma Inc.
In which jurisdiction is Aptose Biosciences Inc. incorporated?
Aptose Biosciences Inc. is incorporated in Canada.
What is the Standard Industrial Classification (SIC) code for Aptose Biosciences Inc.?
The Standard Industrial Classification (SIC) code for Aptose Biosciences Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Stats: 506 words · 2 min read · ~2 pages · Grade level 9.7 · Accepted 2024-11-22 08:05:37
Filing Documents
- f8k_112224.htm (8-K) — 15KB
- exh_991.htm (EX-99.1) — 8KB
- 0001171843-24-006522.txt ( ) — 223KB
- gnw-20190101.xsd (EX-101.SCH) — 3KB
- gnw-20190101_def.xml (EX-101.DEF) — 25KB
- gnw-20190101_lab.xml (EX-101.LAB) — 33KB
- gnw-20190101_pre.xml (EX-101.PRE) — 22KB
- f8k_112224_htm.xml (XML) — 3KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On November 22, 2024, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in the press release attached as Exhibit 99.1 hereto shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release dated November 22, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aptose Biosciences Inc. Date: November 22, 2024 By: /s/ William G. Rice, Ph.D. William G. Rice, Ph.D. President and Chief Executive Officer